Lack of direct involvement of a diazepam long-term treatment in the occurrence of irreversible cognitive impairment: a pre-clinical approach.


Journal

Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664

Informations de publication

Date de publication:
03 12 2021
Historique:
received: 26 02 2021
accepted: 25 10 2021
revised: 20 09 2021
entrez: 3 12 2021
pubmed: 4 12 2021
medline: 1 2 2022
Statut: epublish

Résumé

Several observational studies have found a link between the long-term use of benzodiazepines and dementia, which remains controversial. Our study was designed to assess (i) whether the long-term use of benzodiazepines, at two different doses, has an irreversible effect on cognition, (ii) and whether there is an age-dependent effect. One hundred and five C57Bl/6 male mice were randomly assigned to the 15 mg/kg/day, the 30 mg/kg/day diazepam-supplemented pellets, or the control group. Each group comprised mice aged 6 or 12 months at the beginning of the experiments and treated for 16 weeks. Two sessions of behavioral assessment were conducted: after 8 weeks of treatment and after treatment completion following a 1-week wash-out period. The mid-treatment test battery included the elevated plus maze test, the Y maze spontaneous alternation test, and the open field test. The post-treatment battery was upgraded with three additional tests: the novel object recognition task, the Barnes maze test, and the touchscreen-based paired-associated learning task. At mid-treatment, working memory was impaired in the 15 mg/kg diazepam group compared to the control group (p = 0.005). No age effect was evidenced. The post-treatment assessment of cognitive functions (working memory, visual recognition memory, spatial reference learning and memory, and visuospatial memory) did not significantly differ between groups. Despite a cognitive impact during treatment, the lack of cognitive impairment after long-term treatment discontinuation suggests that benzodiazepines alone do not cause irreversible deleterious effects on cognitive functions and supports the interest of discontinuation in chronically treated patients.

Identifiants

pubmed: 34857741
doi: 10.1038/s41398-021-01718-8
pii: 10.1038/s41398-021-01718-8
pmc: PMC8640018
doi:

Substances chimiques

Diazepam Q3JTX2Q7TU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

612

Informations de copyright

© 2021. The Author(s).

Références

J Clin Neurol. 2019 Jan;15(1):9-19
pubmed: 30375757
J Cereb Blood Flow Metab. 2019 Jun;39(6):1015-1025
pubmed: 29333917
Oxid Med Cell Longev. 2017;2017:3037876
pubmed: 29098059
Neurosci Biobehav Rev. 2005;29(8):1193-205
pubmed: 16084592
J Am Med Dir Assoc. 2020 Feb;21(2):201-211.e2
pubmed: 31653534
Exp Aging Res. 1996 Jan-Mar;22(1):73-81
pubmed: 8665988
Eur J Pharmacol. 2018 Jul 15;831:77-86
pubmed: 29738701
Am J Epidemiol. 2019 Jul 1;188(7):1228-1236
pubmed: 31111865
Neuropharmacology. 2019 Sep 1;155:162-172
pubmed: 31132437
Eur J Neurosci. 1998 Jul;10(7):2380-7
pubmed: 9749766
Behav Brain Res. 2020 Apr 6;383:112501
pubmed: 31987935
J Psychiatry Neurosci. 1992 Jun;17(2):72-7
pubmed: 1637802
Drug Alcohol Depend. 1997 Jul 4;46(3):181-90
pubmed: 9250476
Neurobiol Aging. 2009 Apr;30(4):507-14
pubmed: 19231028
Arch Toxicol. 2010 Dec;84(12):939-46
pubmed: 20130842
Prog Neurobiol. 2014 Feb;113:88-94
pubmed: 23978486
Dialogues Clin Neurosci. 2015 Sep;17(3):295-303
pubmed: 26487810
CNS Drugs. 2016 Jan;30(1):1-7
pubmed: 26715389
Prog Neuropsychopharmacol Biol Psychiatry. 2016 Oct 3;70:68-76
pubmed: 27208614
J Clin Monit Comput. 1999 Dec;15(7-8):529-44
pubmed: 12578052
Presse Med. 2018 Oct;47(10):878-881
pubmed: 30454579
Pharmacogenetics. 1993 Dec;3(6):291-301
pubmed: 8148870
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
J Vis Exp. 2018 Nov 20;(141):
pubmed: 30531711
Neuroscience. 1988 Jun;25(3):771-95
pubmed: 2841624
Eur J Neurosci. 2004 Oct;20(8):2214-24
pubmed: 15450101
Aging (Albany NY). 2015 Jun;7(6):370-82
pubmed: 26081073
CNS Drugs. 2018 Jun;32(6):485-497
pubmed: 29926372
Curr Top Behav Neurosci. 2016;28:449-74
pubmed: 27646012
Anesth Prog. 1980 Nov;27(6):175-83
pubmed: 19598594
BMJ. 2014 Sep 09;349:g5205
pubmed: 25208536
Curr Pharm Des. 2002;8(1):1-3
pubmed: 11812246
JAMA Psychiatry. 2015 Feb;72(2):136-42
pubmed: 25517224
ScientificWorldJournal. 2006 Nov 16;6:1460-5
pubmed: 17115086
Handb Exp Pharmacol. 2008;(182):335-60
pubmed: 18175099
Psychopharmacology (Berl). 1998 Aug;138(3-4):344-53
pubmed: 9725757
Behav Neural Biol. 1991 Jan;55(1):131-6
pubmed: 1996944
BMC Public Health. 2020 Jun 1;20(1):818
pubmed: 32487058
Pharmacol Biochem Behav. 2018 Sep;172:59-67
pubmed: 30030126
Pharmacol Biochem Behav. 2001 Feb;68(2):235-44
pubmed: 11267628
BMC Public Health. 2019 May 14;19(1):566
pubmed: 31088561
Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1421-33
pubmed: 19689220
Transl Stroke Res. 2021 Apr;12(2):316-330
pubmed: 32440818
Ann Pharmacother. 2020 Mar;54(3):219-225
pubmed: 31595772
Biomed Res Int. 2013;2013:408573
pubmed: 23971034
Psychopharmacology (Berl). 1990;102(3):373-8
pubmed: 1979181
BMC Geriatr. 2019 Oct 21;19(1):276
pubmed: 31638906
Neuropharmacology. 2019 Jan;144:319-326
pubmed: 30408486
J Pharmacol Toxicol Methods. 2006 Sep-Oct;54(2):99-105
pubmed: 16750402
Z Gerontol Geriatr. 2014 Jun;47(4):279-84
pubmed: 25088385
Eur Addict Res. 2019;25(6):320-329
pubmed: 31494655
JAMA Netw Open. 2020 Oct 1;3(10):e2019029
pubmed: 33119104

Auteurs

Louise Carton (L)

Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, 59000, Lille, France. louise.carton@univ-lille.fr.

Candice Niot (C)

Pharmacy Service, Arras Hospital Center, 62000, Arras, France.

Maéva Kyheng (M)

Univ. Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, 59000, Lille, France.
Département de Biostatistiques, CHU Lille, 59000, Lille, France.

Maud Petrault (M)

Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, 59000, Lille, France.

Charlotte Laloux (C)

Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UMS 2014 - PLBS, Lille In vivo Imaging and Functional Exploration, 59000, Lille, France.

Camille Potey (C)

Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, 59000, Lille, France.

Marie Lenski (M)

Univ. Lille, CHU Lille, Institut Pasteur de Lille, ULR 4483 - IMPECS - Impact de l'Environnement Chimique sur la Santé, 59000, Lille, France.

Régis Bordet (R)

Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, 59000, Lille, France.

Julie Deguil (J)

Univ. Lille, Inserm, CHU Lille, Lille Neuroscience and Cognition, Degenerative and Vascular Cognitive Disorders, UMR-S1172, 59000, Lille, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH